Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CHE
CHE logo

CHE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Chemed Corp (CHE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
382.880
1 Day change
1.40%
52 Week Range
623.610
Analysis Updated At
2026/04/10
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Chemed Corp (CHE) does not present a compelling buy opportunity for a beginner investor with a long-term horizon at this time. While the stock has potential upside based on analyst valuations, the recent financial performance, analyst downgrades, and lack of strong positive catalysts suggest waiting for clearer signs of recovery or value unlocking.

Technical Analysis

The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 63.269, and moving averages are converging, showing no strong directional trend. The stock closed at $390.85, near the R1 resistance level of $393.994, but there is no clear breakout signal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market. However, implied volatility is high (IV percentile: 83.2), suggesting elevated uncertainty.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
3

Positive Catalysts

  • Analysts see potential value unlocking through a separation of the Roto-Rooter and Vitas businesses, with a price target range of $426-$588, representing up to 59% upside. Oppenheimer maintains an Outperform rating with a $500 price target.

Neutral/Negative Catalysts

  • Recent financial performance shows declining revenue (-0.10% YoY), net income (-15.02% YoY), and EPS (-8.96% YoY). Roto-Rooter continues to face margin headwinds, and multiple analysts have downgraded the stock due to disappointing Q4 results and a weak 2026 outlook. Hedge funds are also selling the stock, with a 158.47% increase in selling activity last quarter.

Financial Performance

In Q4 2025, Chemed reported a YoY decline in revenue (-0.10%), net income (-15.02%), and EPS (-8.96%). Gross margin also dropped to 32.67%, down 4.22% YoY, indicating operational challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed but leaning negative. Oppenheimer maintains an Outperform rating with a $500 price target, citing long-term value creation potential. However, RBC, BofA, and Jefferies have downgraded the stock due to Roto-Rooter's persistent margin issues and disappointing Q4 results.

Wall Street analysts forecast CHE stock price to rise
3 Analyst Rating
Wall Street analysts forecast CHE stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 382.880
sliders
Low
475
Averages
547.33
High
595
Current: 382.880
sliders
Low
475
Averages
547.33
High
595
Oppenheimer
Oppenheimer
maintain
$500
AI Analysis
2026-03-31
Reason
Oppenheimer
Oppenheimer
Price Target
$500
AI Analysis
2026-03-31
maintain
Reason
Oppenheimer still believes Chemed can unlock Roto-Rooter's value operationally. However, it makes sense to looking at the value of the two companies separately given their lack of synergies and changes to the business, the analyst tells investors in a research note. Oppenheimer applied a 12-18 times multiple on the Roto-Rooter business, equating to $2.3B to $3.5B. Potential value can be unlocked by splitting up the companies, contends the firm. Its analysis puts the total value of Chemed at a $5.6B to $7.8B enterprise value, which translates to $426-$588 per share, or upside potential of 16%-59% from current levels. As such, the analyst recommends being long-term buyer of the stock. Oppenheimer has an Outperform rating on Chemed with a $500 price target. The stock in morning trading is up 1% to $378.27.
Oppenheimer
Michael Wiederhorn
Outperform
to
NULL
downgrade
$580 -> $500
2026-02-27
Reason
Oppenheimer
Michael Wiederhorn
Price Target
$580 -> $500
2026-02-27
downgrade
Outperform
to
NULL
Reason
Oppenheimer analyst Michael Wiederhorn lowered the firm's price target on Chemed to $500 from $580 and keeps an Outperform rating on the shares. The firm notes Chemed reported a Q4 miss, with one-third due to Vitas and two-thirds due to Roto-Rooter. However, Vitas has already created cap buffer in Florida, and is currently working through the related mix-pressures. While Oppenheimer sees long-term value creation opportunity in the consolidated portfolio following this earnings/outlook/pullback, but argues that, if necessary, there is an opportunity to unlock value by breaking up the company.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CHE
Unlock Now

People Also Watch